Camac: Forte Biosciences Capital Raise 'Seemingly Defensive and Unjustifiable'

 Fears the Board has Diluted Shareholders for Self-Serving Purposes Following the Emergence of Four 13D Filers, Suggesting the Directors Have Potentially Breached Their Fiduciary Duties

Notes the Company Trades at a ~40% Discount to Cash

Urges the Board to Reverse Course and Return Capital to Long-Suffering Shareholders – or Risk Facing Action from Camac

https://finance.yahoo.com/news/camac-partners-condemns-forte-biosciences-120000741.html